Inspiremd Inc (NSPR)

$2.66

+0.02

(+0.76%)▲

Market is closed - opens 7 PM, 05 Jun 2024

Insights on Inspiremd Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.76M → 1.51M (in $), with an average decrease of 14.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -4.13M → -7.03M (in $), with an average decrease of 14.8% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 129.8%

Performance

  • $2.60
    $2.69
    $2.66
    downward going graph

    2.26%

    Downside

    Day's Volatility :3.34%

    Upside

    1.11%

    downward going graph
  • $1.64
    $3.85
    $2.66
    downward going graph

    38.35%

    Downside

    52 Weeks Volatility :57.4%

    Upside

    30.91%

    downward going graph

Returns

PeriodInspiremd IncIndex (Russel 2000)
3 Months
2.72%
0.0%
6 Months
7.76%
0.0%
1 Year
52.6%
0.0%
3 Years
-50.19%
-22.6%

Highlights

Market Capitalization
68.6M
Book Value
$1.5
Earnings Per Share (EPS)
-0.5
PEG Ratio
0.0
Wall Street Target Price
4.5
Profit Margin
0.0%
Operating Margin TTM
-490.67%
Return On Assets TTM
-48.78%
Return On Equity TTM
-93.55%
Revenue TTM
6.5M
Revenue Per Share TTM
0.21
Quarterly Revenue Growth YOY
22.0%
Gross Profit TTM
1.1M
EBITDA
-23.9M
Diluted Eps TTM
-0.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.82
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Inspiremd Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 69.17%

Current $2.66
Target $4.50

Company Financials

FY18Y/Y Change
Revenue
3.6M
↑ 30.42%
Net Income
-7.2M
↓ 14.2%
Net Profit Margin
-201.06%
↑ 104.55%
FY19Y/Y Change
Revenue
3.7M
↑ 3.33%
Net Income
-10.0M
↑ 38.67%
Net Profit Margin
-269.82%
↓ 68.76%
FY20Y/Y Change
Revenue
2.5M
↓ 33.22%
Net Income
-10.5M
↑ 5.02%
Net Profit Margin
-424.31%
↓ 154.49%
FY21Y/Y Change
Revenue
4.5M
↑ 80.89%
Net Income
-14.9M
↑ 41.48%
Net Profit Margin
-331.88%
↑ 92.43%
FY22Y/Y Change
Revenue
5.2M
↑ 15.04%
Net Income
-18.5M
↑ 23.95%
Net Profit Margin
-357.59%
↓ 25.71%
FY23Y/Y Change
Revenue
6.2M
↑ 20.0%
Net Income
-19.9M
↑ 7.71%
Net Profit Margin
-320.97%
↑ 36.62%
Q4 FY22Q/Q Change
Revenue
1.0M
↓ 28.3%
Net Income
-4.8M
↑ 8.93%
Net Profit Margin
-472.22%
↓ 161.39%
Q1 FY23Q/Q Change
Revenue
1.2M
↑ 20.76%
Net Income
-4.1M
↓ 14.74%
Net Profit Margin
-333.41%
↑ 138.81%
Q2 FY23Q/Q Change
Revenue
1.6M
↑ 33.09%
Net Income
-5.1M
↑ 22.9%
Net Profit Margin
-307.88%
↑ 25.53%
Q3 FY23Q/Q Change
Revenue
1.6M
↓ 5.64%
Net Income
-5.2M
↑ 1.99%
Net Profit Margin
-332.78%
↓ 24.9%
Q4 FY23Q/Q Change
Revenue
1.8M
↑ 13.17%
Net Income
-5.4M
↑ 4.38%
Net Profit Margin
-306.93%
↑ 25.85%
Q1 FY24Q/Q Change
Revenue
1.5M
↓ 14.2%
Net Income
-7.0M
↑ 30.1%
Net Profit Margin
-465.39%
↓ 158.46%
FY18Y/Y Change
Total Assets
12.3M
↑ 101.21%
Total Liabilities
3.5M
↑ 4.29%
FY19Y/Y Change
Total Assets
9.9M
↓ 19.6%
Total Liabilities
4.5M
↑ 27.57%
FY20Y/Y Change
Total Assets
17.8M
↑ 79.93%
Total Liabilities
5.6M
↑ 24.84%
FY21Y/Y Change
Total Assets
39.7M
↑ 123.39%
Total Liabilities
6.2M
↑ 10.08%
FY22Y/Y Change
Total Assets
24.7M
↓ 37.92%
Total Liabilities
7.3M
↑ 17.48%
FY23Y/Y Change
Total Assets
47.6M
↑ 93.25%
Total Liabilities
8.1M
↑ 12.15%
Q4 FY22Q/Q Change
Total Assets
24.7M
↓ 12.14%
Total Liabilities
7.3M
↑ 17.27%
Q1 FY23Q/Q Change
Total Assets
19.9M
↓ 19.19%
Total Liabilities
6.5M
↓ 10.54%
Q2 FY23Q/Q Change
Total Assets
53.6M
↑ 169.25%
Total Liabilities
6.8M
↑ 5.08%
Q3 FY23Q/Q Change
Total Assets
50.0M
↓ 6.75%
Total Liabilities
6.8M
↓ 0.91%
Q4 FY23Q/Q Change
Total Assets
47.6M
↓ 4.75%
Total Liabilities
8.1M
↑ 20.39%
Q1 FY24Q/Q Change
Total Assets
42.0M
↓ 11.79%
Total Liabilities
6.9M
↓ 14.75%
FY18Y/Y Change
Operating Cash Flow
-7.6M
↓ 6.46%
Investing Cash Flow
-44.0K
↓ 86.16%
Financing Cash Flow
13.4M
↑ 188.58%
FY19Y/Y Change
Operating Cash Flow
-9.8M
↑ 28.98%
Investing Cash Flow
-387.0K
↑ 779.55%
Financing Cash Flow
6.3M
↓ 52.62%
FY20Y/Y Change
Operating Cash Flow
-9.1M
↓ 7.43%
Investing Cash Flow
-187.0K
↓ 51.68%
Financing Cash Flow
16.4M
↑ 158.8%
FY21Y/Y Change
Operating Cash Flow
-13.2M
↑ 45.47%
Investing Cash Flow
-22.5M
↑ 11909.09%
Financing Cash Flow
35.0M
↑ 113.69%
FY22Y/Y Change
Operating Cash Flow
-15.5M
↑ 17.65%
Investing Cash Flow
8.4M
↓ 137.59%
Financing Cash Flow
-140.0K
↓ 100.4%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.2M
↓ 37.4%
Investing Cash Flow
3.9M
↑ 41.1%
Financing Cash Flow
37.5M
↓ 36540.78%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.8M
↑ 51.21%
Investing Cash Flow
4.4M
↑ 14.49%
Financing Cash Flow
37.5M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.3M
↓ 31.17%
Investing Cash Flow
-26.9M
↓ 704.43%
Financing Cash Flow
37.5M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Inspiremd Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inspiremd Inc
Inspiremd Inc
24.53%
7.76%
52.6%
-50.19%
-94.99%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.57%
46.89%
79.16%
88.7%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
26.96%
1.71%
-9.27%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inspiremd Inc
Inspiremd Inc
NA
NA
0.0
-0.82
-0.94
-0.49
NA
1.5
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inspiremd Inc
Inspiremd Inc
Buy
$68.6M
-94.99%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
88.7%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • Nantahala Capital Management, LLC

    17.64%

  • Orbimed Advisors, LLC

    9.11%

  • Marshall Wace Asset Management Ltd

    7.94%

  • Soleus Capital Management, L.P.

    5.88%

  • Velan Capital Investment Management LP

    3.86%

  • Rosalind Advisors, Inc.

    2.93%

Company Information

inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.

Organization
Inspiremd Inc
Employees
68
CEO
Mr. Marvin L. Slosman
Industry
Health Technology

Discover More

FAQs